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Background: The FDA recently approved an anti-CTLA-4 antibody (Iplimumab) for the treatment of metastatic
melanoma. This decision was based on Phase III results, which demonstrate that blocking this immune checkpoint
provides a survival advantage in patients with advanced disease. As a single agent, ipilimumab is also being
clinically evaluated in advanced (metastatic, castrate-resistant) prostate cancer and two randomized, placebo-
controlled Phase III studies have recently completed accrual.
Methods: We used a well-described genetically engineered mouse (GEM), autochronous prostate cancer model
(Pro-TRAMP) to explore the relative sequencing and dosing of anti-CTLA-4 antibody when combined with a cell-
based, GM-CSF-secreting vaccine (GVAX).
Results: Our results show that combined treatment results in a dramatic increase in effector CD8 T cells in the
prostate gland, and enhanced tumor-antigen directed lytic function. These effects are maximized when CTLA-4
blockade is applied after, but not before, vaccination. Additional experiments, using models of metastatic disease,
show that incorporation of low-dose cyclophosphamide into this combined treatment regimen results in an
additional pre-clinical benefit.
Conclusions: Together these studies define a combination regimen using anti-CTLA-4/GVAX immunotherapy and
low-dose chemotherapy for potential translation to a clinical trial setting.
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Prostate cancer is the most prevalent non-dermatologic
malignancy and the third most common cause of cancer-
related death among men in developed countries. In the
United States, 217,730 men were diagnosed with prostate
cancer in 2010 and 32,050 died from the disease [1]. While
localized tumors can be cured by surgical resection or
radiotherapy, and early metastatic disease is frequently re-
sponsive to androgen ablation, docetaxel-based chemother-
apy is a mainstay of treatment in the setting of progression
from androgen-sensitive to castrate-resistant disease [2].
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reproduction in any medium, provided the ormodest benefit from chemotherapy [3]. Recently, meta-
static castrate-resistant prostate cancer (mCRPC) has been
shown to remain sensitive to hormonal manipulation [4],
and the androgen biosynthesis inhibitor abiraterone acetate
is now FDA-approved in the post-docetaxel setting [5].
The novel anti-androgen enzalutamide (MDV3100) has
also completed Phase III testing, with positive data
reported [6]. Despite these important advances, mCRPC
remains incurable in the majority of men, necessitating de-
velopment of alternative treatment modalities.
With the landmark FDA approval of sipleucel-T (Provenge),
prostate cancer emerged as a valid target for cancer im-
munotherapy [7]. Prostate cancer may be especially well-
suited to this treatment approach given the non-vital
nature of the prostate gland and the existence of a
number of well-characterized prostate-restricted anti-
gens [8]. In addition to sipleucel-T, several othertd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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progressed to Phase II or Phase III clinical trials. One
such therapy is GVAX (GM-CSF immunotherapy for
cancer), which involves intradermal administration of
irradiated, allogeneic tumor cells genetically modified
to secrete granulocyte-macrophage colony-stimulating
factor (GM-CSF) [9]. Despite promising results in pre-
clinical and early clinical testing, two Phase III clinical
trials of GVAX for advanced castration-resistant prostate
cancer were halted [8]. There are a variety of potential rea-
sons for the failure of GVAX immunotherapy to dem-
onstrate clinical benefit in prostate cancer [8]. One
possibility is that repeated exposure to high doses of
GM-CSF could drive the induction of a regulatory
population of cells known as myeloid-derived suppres-
sor cells [10]. A second, more intriguing possibility is
that persistent exposure to tumor antigens in the setting
of advanced disease induces T cell tolerance, thus limiting
the effectiveness of a vaccine strategy. Emerging data sug-
gest that this effect may be at least partially obviated by
combining immunotherapy (i.e. vaccines) with agents
designed to block the immune checkpoints that limit an
anti-tumor immune response [11].
Ipilimumab (Yervoy, BMS Princeton, NJ), a fully hu-
man anti-Cytotoxic T Lymphocyte Antigen-4 (CTLA-4)
monoclonal antibody, was recently approved by the FDA
for the treatment of metastatic and unresectable melan-
oma [12]. CTLA-4 is the most extensively studied im-
mune checkpoint molecule, and is expressed on activated
T effector cells (Teffs) [13] and T regulatory cells (Tregs)
[14]. In contrast to CD28/B7 binding, which acts as a co-
stimulatory signal to promote T cell activation and pro-
liferation, the binding of CTLA-4 to B7 transmits an
inhibitory signal. While CTLA-4 blockade has been
shown to have powerful anti-cancer effects in some pa-
tients, it has also been associated with a significant risk
of autoimmune toxicity. For example, a Phase III clin-
ical trial of ipilimumab in patients with metastatic mel-
anoma reported a survival benefit and an overall response
rate of 11% with ipilimumab alone; however, approxi-
mately 60% of patients demonstrated immune-related
adverse events and 7 patients (1.1%) died from immune-
related adverse events (IRAEs) [15]. These complications
may be partially reflected in mouse models as CTLA-4
knockout mice die of multi-organ failure at ~3-4 weeks
of age secondary to lymphoproliferation [16].
Previous studies in murine prostate cancer models
have demonstrated that CTLA-4 blockade promotes
anti-tumor activity [17] and works synergistically with
GM-CSF-expressing tumor vaccines [18]. Given the sig-
nificant rate of IRAEs observed in the recent clinical trials
described above, we sought to determine the minimum
dose of anti-CTLA-4 required for additive efficacy, as well
as the optimal sequence of cell-based immunotherapy(GVAX) and checkpoint blockade. These studies utilized
our well-established genetically engineered mouse (GEM)
model, in which the model antigen hemagglutinin (HA) is
expressed in a prostate-restricted manner on the trans-
genic adenocarcinoma of the mouse prostate (TRAMP)
background [19-23].
We subsequently tested this regimen in models of lung
and liver metastasis in wild type mice as well as mice har-
boring synchronous prostate tumors. Finally, we added low-
dose cyclophosphamide to evaluate a potential role for T
regulatory cells in limiting the anti-tumor response [23].
Overall, our data confirm the finding that combining GVAX
immunotherapy with CTLA-4 blockade is more effective
than either treatment alone. Interestingly, we found that
CTLA-4 blockade must be administered subsequent to vac-
cination to produce additive immunologic effects. Low-dose
cyclophosphamide provided a benefit when added to this
combination regimen, suggesting that CTLA-4 blockade
does not completely mitigate Treg function.
Materials and methods
All studies were completed under an protocol approved
by the Johns Hopkins Animal Care and Use Committee.
Mice
Non-transgenic B10.D2 (H-2d) mice were purchased from
the Jackson Laboratory. Pro-HA transgenic mice express a
secreted form of Hemagglutinin (HA) under control of
the prostate epithelial-specific Probasin promoter [19],
and are on the B10.D2 (H-2d) genetic background. Double
transgenic (ProHA × TRAMP) mice were generated by
backcrossing TRAMP (Transgenic Adenocarcinoma of
the Mouse Prostate) animals on a C57/Bl6 background
onto the ProHA transgenic background > 12 generations,
and are homozygous for H-2d at the MHC locus. As previ-
ously described [19], ProHA × TRAMP mice develop au-
tochthonous prostate tumors that express HA as a tissue/
tumor-restricted antigen. Otherwise, disease development
is indistinguishable from their TRAMP counterparts
[19-21]. Clone 4 transgenic mice express a CD8 TCR
which is specific for the Kd-restricted (MHC Class I) HA
peptide (542IYSTVASSL550) [24]. 6.5 mice are CD4 TCR
transgenic animals with a TCR specific for the I-Ed re-
stricted (MHC Class II) HA peptide (110SFERFEIFPKE120)
[25]. For these studies, Clone 4 and 6.5 mice were
backcrossed over 12 generations onto a Thy1.1 congenic
B10.D2 background. Mouse care and experimental proce-
dures were carried out in accordance with the Institu-
tional Animal Care and Use Committee of Johns Hopkins
University under an approved protocol.
Cell lines
The prostate adenocarcinoma cell line, TRAMP-C2, was
purchased from ATCC (Manassas, VA). To construct a
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transfected with full-length HA as previously described
[26]. Transfectants were cloned by limiting dilution in 96
well plates, and HA expression was confirmed by staining
with the HA-specific mAb H18L10-5R1 [27], which was
graciously provided by Dr. J. Yewdell (NIAID). A single
clone expressing high-levels of HA was selected, expanded
and used in further studies. B78H1-GM is a GM-CSF se-
creting cell line utilized in bystander immunotherapy regi-
mens [28], as previously described [29]. B78H1-GM cells
secrete approximately 2500 ng of GM-CSF per 106 cells
over a 24-hour period, as determined by ELISA. The SP1
cell line was established from ProHA × TRAMP mice
(prostate tumor) in our laboratory and maintained in
RPMI 1640 supplemented with 10% heat inactivated FCS
(HyClone, South Logan, UT), 1 mmol/L sodium pyruvate,
2 mmol/L L-glutamine, nonessential amino acids (1% of
100× stock), 25 mmol/L HEPES buffer, and 50 μmol/L
2-mercaptoethanol (C-Media).
Reagents
Cyclophosphamide was purchased from Bristol-Myers
Squibb, and diluted in PBS for intraperitoneal injection.
Anti-CTLA-4 mAb was purified by protein G chromatog-
raphy from supernatants of the clone UC10-4 F10-11 hy-
bridoma obtained from American Type Culture Collection.
Adoptive T cell transfer
Adoptive T cell transfer was performed as previously de-
scribed [19]. Donor TCR transgenic mice were euthanized
via CO2 asphyxiation. Spleens and lymph nodes were col-
lected, homogenized, and red blood cells were lysed. CD8
or CD4 T cells were purified using Miltenyi beads
according to the manufacturer’s protocol. For some exper-
iments, purified cells were labeled for 8 minutes with
CFSE (Invitrogen) by adding 0.5 μl of 5 mM stock per
1 ml cells After labeling, cells were washed twice and
resuspended in HBSS. 2.5 × 106 cells in 200 μL were
injected per mouse by tail vein injection.
GVAX Immunotherapy
To model allogeneic prostate GVAX immunotherapy using
bystander cells, 1×106 TRAMP-C2HA cells were admixed
with 5×104 B78H1-GM cells and irradiated (50 Gy). After
three washes in HBSS, cells were resuspended in a total of
200 μl of HBSS and administered by subcutaneous injec-
tion of 100 μl into each hind limb [23]. For the metastatic
treatment studies, the cell line SP1 (see below) was used to
generate the GVAX vaccine, which was produced and ad-
ministered in the same manner.
Flow cytometry
Prostate glands, prostate-draining lymph nodes and
spleens were harvested on predetermined days andsingle cell suspensions were prepared. All staining re-
agents were purchased from BD Pharmingen (San Diego,
CA), with the exception of FoxP3, which was analyzed
using an eBioscience antibody according to the manufac-
turer’s instructions (eBioscience, San Diego, CA). After a
30-minute incubation period, samples were washed once
in PBS-1%FBS solution and analyzed using a FACScalibur
instrument (BD, San Jose, CA). Intracellular cytokine ana-
lysis was performed as previously described [21]. Data
were analyzed using the FlowJo software package
(Treestar, Ashland, OR).In vivo CTL assay
In vivo CTL assays were performed as previously de-
scribed [30]. Splenocytes from naive B10.D2 mice were la-
beled with 2.5 or 0.25 μM CFSE (Molecular Probes,
Eugene, OR). 2.5 μM CFSE-labeled cells were loaded with
HA class I peptide (10 μmol/L), while 0.25 μM CFSE-
labeled cells were used as a negative control. Target cells
were transferred intravenously (7.5 × 106 cells of each
population) into indicated groups of mice. Eighteen hours
later, lymphocytes were isolated from the spleen and FACS
analysis was performed. Histogram plots were used to de-
termine the percentage of each target population based on
the intensity of CFSE staining. Percentage-specific killing
was calculated as previously described [31].Efficacy studies
Treatment was initiated when ProHA × TRAMP mice
were 8–10 weeks of age [32]. Immunization was performed
a total of three times at 1 week intervals unless otherwise
indicated. Mice were euthanized at 18–20 weeks of age
and the male urogenital tracts were micro-dissected under
a stereomicroscope and weighed. Ventral prostate lobes
were removed and fixed in 10% neutral buffered formalin
followed by 70% EtOH. Tissues were then embedded in
paraffin, cut into four micron sections using a cryostat, and
placed onto poly-lysine-coated slides before being stained
with H&E. Tumor tissues were graded in a blinded manner
by two individual pathologists as previously described [21]:
0 = normal epithelium; 1 = prostatic intraepithelial neopla-
sia (PIN) with tufting of the epithelium but without
cribiform structures; 2 = advanced PIN with cribiform
structures; 3 = loss of intraductal spaces and/or basement
membrane invasion (well differentiated carcinoma);
4 = moderately differentiated adenocarcinoma; 5 = poorly
differentiated adenocarcinoma or small cell carcinoma.
Prostates containing regions that differed morpho-
logically were assigned a grade reflecting the most
prevalent region. Tumors were also graded according to
the extent of involvement: 1 = focal; 2 =multi-focal; 3 =
diffuse. Tumor score was calculated as tumor grade ×
tumor extent.
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To model prostate cancer metastatic to the liver, tumor
cells were injected into the hemi-spleens of ProHA ×
TRAMP mice or B10.D2 mice using a previously de-
scribed surgical procedure [33]. Briefly, the spleens of
anesthetized mice were divided into halves and each half
individually clipped. SP1 cells (1.0 × 105) were injected
into one hemispleen. After 30 seconds, the injected
hemispleen was resected and the corresponding splenic
vein was clipped. For the pulmonary metastasis model,
tail vein injection of 1.0 × 105 SP1 cells suspended in
200 μl HBSS using a 26-guage needle was performed.
GVAX immunotherapy using SP1 cells (see above) was
administered 3 days after tumor injection and anti-
CTLA-4 mAb was injected per the indicated schedule.
Cyclophosphamide (50 mg/kg) was administered 1 day
before GVAX.
Statistical analyses
Unless otherwise indicated, each experiment was performed
in triplicate using a minimum of 5 animals per group. Rep-
resentative results are shown. Mean ± SEM is shown. For
comparisons between groups, a one-way ANOVA with
post-test comparison was performed. A log-rank test was
performed for survival. Differences were considered statisti-
cally significant for two-sided p values < 0.05. Calculations
were performed using the GraphPad PRISM package
(GraphPad, La Jolla, CA).
Results
Combination therapy with anti-CTLA-4 monoclonal
antibody and GVAX immunotherapy promotes
proliferation of tumor antigen-specific CD8 T cells
To evaluate the systemic immunologic effects of cell-
based immunotherapy (GVAX) in either non-transgenic
or tumor-bearing ProHA × TRAMP mice, we adoptively
transferred CFSE-labeled, HA-specific CD8 T cells. The
proliferation and effector function of these cells reflects
the relative efficacy of vaccination in the respective
strains. Proliferation of HA-specific CD8 T cells (which
represent prostate/prostate-cancer specific T cells in this
model) was assessed by dilution of CFSE. As shown in
Figure 1A, GVAX immunotherapy resulted in a robust in-
crease in the percentage of divided CD8 T cells specific for
HA in both tumor-bearing and non-transgenic recipients.
Division peaked approximately 7 days post-vaccine admin-
istration in non-transgenic mice, but plateaued on day 4
in tumor bearing mice. As is typical for naïve CD8 T cells,
some background proliferation was detectable in non-
transgenic animals. To determine whether expression of
the immune checkpoint molecule CTLA-4 could poten-
tially be restraining the vaccine response of prostate/
prostate cancer specific cells, we stained the prostate-
specific CD8 T cells for CTLA-4 expression. As shownin Figure 1B, CTLA-4 expression in the prostate-
draining lymph nodes was noted on day 4, with approxi-
mately 16% of divided cells staining positive. By day 7,
expression was more robust; at this time point approxi-
mately 45% of the HA-specific CD8 cells in the draining
lymph node expressed CTLA-4. In the tumor-bearing
prostate gland itself, more than half of the specific CD8
T cells expressed CTLA-4. Taken together, these data
show that GVAX vaccination induces a detectable, but
relatively blunted CD8 T cell response in prostate
tumor-bearing mice, and this blunted response corre-
lates with CTLA-4 expression on specific T cells, espe-
cially in the target organ.
Based on these data, we evaluated the ability of a
CTLA-4 blocking monoclonal antibody to augment
vaccine-mediated proliferation, once again using either
non-transgenic, or tumor bearing mice (ProHA × TRAMP).
Animals received infusions of CFSE-labeled HA-specific
CD8 T cells as readout for vaccine (+/− antibody) ef-
ficacy. As expected, anti-CTLA-4 treatment alone did
not significantly increase the percentage of divided
HA-specific CD8 T cells in either tumor bearing or
non-tumor bearing mice (Figure 1C). In tumor bearing
mice, combination therapy significantly increased the
percentage of HA-specific CD8 T cells as compared with
GVAX treatment alone, while in non-tumor bearing
mice, the addition of anti-CTLA-4 mAb did not sig-
nificantly increase the percentage of HA-specific T
cells beyond the effect observed with GVAX alone.
These data support the concept of GVAX+ anti-CTLA-4
combination therapy, and suggest that the effects of
combination treatment may be more pronounced in
the presence of cancer.
Timing and dosage of anti-CTLA-4 antibody is critical for
augmenting GVAX immunotherapy
The treatment schema used in Figure 1C was empiric;
we attempted to relatively saturate CTLA-4 with anti-
body by treating with three doses 2 days apart. To more
directly examine the immunological effects of combin-
ation treatment in tumor-bearing mice, we performed a
series of studies varying the relative timing of vaccin-
ation and CTLA-4 blockade, in either non-transgenic or
tumor-bearing ProHA × TRAMP mice. We also used a
more functional readout for efficacy, in vivo lysis of HA-
loaded target cells by the endogenous (as opposed to
adoptively transferred) CD8 T cell population. In tumor-
free, non-transgenic mice, GVAX vaccination alone
resulted in a significant CTL response detectable 7 days
after vaccination (Figure 2A). Administration of 2 doses
(5 mg/kg) of anti-CTLA-4 after vaccination increased
the relative CTL response as compared to GVAX vaccin-
ation alone. Interestingly, in non-transgenic mice, the
opposite sequence was not successful. Administration of
Figure 1 GVAX Immunotherapy induces CTLA-4 expression on tumor-specific CD8 T cells. A: Blunted CD8 T cell response to GVAX
immunotherapy in tumor-bearing mice. CFSE-labeled HA-specific CD8 T Cells (Clone 4) were adoptively transferred to non-transgenic mice (B10.
D2) or tumor bearing mice (ProHA x TRAMP), and allowed to equilibrate in vivo for 2 days prior to treatment with GVAX immunotherapy (Day 0).
Peripheral blood cells were harvested by tail vein aspiration on the indicated days post-immunization. Data shown are gated on HA-specific CD8+
Thy1.1+ lymphocytes. Mean ± SEM shown, 5 animals per group, representative of 2 experiments. *P < 0.05 (GVAX treated ProHA x TRAMP vs. Non-
Transgenic). B: CTLA-4 expression in tumor-specific CD8 T Cells. Top panel: indicated organs were harvested on day 4 and day 7 post-
immunization. Data shown are gated on HA-specific CD8+ Thy1.1+ lymphocytes that divided at least once. CTLA-4 expression was determined by
intracellular staining. Mean ± SEM shown, 3 animals per group, representative of 2 experiments. Bottom panel: representative dot plots for CFSE
and CTLA-4 staining, gated on HA-specific (CD8+ Thy1.1+) T cells. C: Effects of CTLA-4 blockade on expansion of HA-specific CD8+ T Cells. CFSE-
labeled HA-specific CD8+ T Cells were adoptively transferred to indicated mice and animals were treated 2 days post-transfer with GVAX
immunotherapy (Day 0). Anti-CTLA-4 was administered on the indicated days. Peripheral blood cells were harvested on indicated days. Data
shown are gated on HA-specific CD8+ Thy1.1+ lymphocytes. Mean ± SEM shown, 5 animals per group, representative of 2 experiments.*P < 0.05
(GVAX/anti-CTLA-4 vs. GVAX alone).
Wada et al. Journal of Translational Medicine 2013, 11:89 Page 5 of 14
http://www.translational-medicine.com/content/11/1/89anti-CTLA-4 before vaccination did not increase the
specific CTL response and, in fact, the response appeared
to be slightly diminished. In non-transgenic mice, the dif-
ference between these two sequences was statistically sig-
nificant, with checkpoint blockade clearly demonstrating
greater efficacy when given after vaccination.
We next performed similar studies in tumor-bearing
ProHA × TRAMP mice (Figure 2B). Since multiple pre-
vious studies by our group have shown that a single doseof GVAX in tumor-bearing mice does not induce a detect-
able lytic response [23], we gave two doses of vaccine,
spaced one week apart, in this study. As in non-transgenic
mice, the lytic response in tumor-bearing mice was opti-
mal when anti-CTLA-4 was administered after vaccin-
ation. Interestingly, giving anti-CTLA-4 several days post
vaccination still augmented the CTL response, as might
be suggested by the kinetics of CTLA-4 expression shown
in Figure 1. We also evaluated a more extensive anti-
Figure 2 Time-dependent augmentation of anti-tumor CD8 T cell response by the addition of CTLA-4 blockade to GVAX
immunotherapy. A: Timing of GVAX immunotherapy and CTLA-4 blockade in non-transgenic mice. Top panel shows experimental design.
Readout was HA-specific lytic function quantified by an in vivo CTL analysis. Endogenous T cell lytic function was assayed; no adoptive T cell
transfer was performed. 5 animals per group, representative of 2 experiments. B: Timing of GVAX immunotherapy and CTLA-4 blockade in tumor-
bearing, ProHA x TRAMP mice. Top panel: experimental design. Bottom panel: CTL function in ProHA x TRAMP mice. As in Figure 2A these studies
were performed without adoptive T cell transfer, i.e. endogenous T cell lytic activity was assayed. 5 animals per group, representative of 2
experiments. C: Effects of more frequent anti-CTLA-4 administration. Experimental design (top panel) is identical to Figure 2B, with the exception
of more frequent anti-CTLA-4 administration. 5 animals per group, representative of 2 experiments. D: Day 0 vs. Day 1 anti-CTLA4 dosing.
Experimental design (top panel). Dosing of anti-CTLA-4 on Day 1 was directly compared with same day (Day 0) GVAX/anti-CTLA-4 dosing. 5
animals per group, representative of 2 experiments.
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CTL-4 were administered with each GVAX vaccine dose.
As shown in Figure 2C, optimal timing of vaccination and
checkpoint blockade was not affected by this more inten-
sive treatment protocol; once again maximum lytic func-
tion was observed with anti-CTLA-4 administration one
day post vaccination. Due to the expected convenience of
same-day dosing in a clinical setting, we also examined
whether anti-CTLA-4 blockade could be given at the
same time as GVAX vaccination. We found no significant
difference between administering anti-CTLA-4 on day 1vs. day 0 (Figure 2D). Taken together, these data support a
combination regimen in which anti-CTLA-4 is adminis-
tered on the day of or following GVAX immunotherapy.
As clinical data suggest that the development of IRAEs
is dose-dependent (www.fda.gov), we next sought to de-
termine the minimal dose of anti-CTLA-4 mAb required
to achieve additive effects. In these studies, we once
again tested the effects of a single antibody treatment
per vaccine (Figure 3A) as well as a more dose dense
regimen (Figure 3B). We found that a dose of 6 mg/kg
in a once-per-week dosing paradigm was significantly
Figure 3 Optimization of anti-CTLA-4 dosing in combination with GVAX immunotherapy. A: Titration of anti-CTLA-4 using once per week
dosing. Top panel: experimental design. Bottom panel: CTL function in ProHA x TRAMP mice. 5 animals per group, representative of 2
experiments. B: Titration of anti-CTLA-4 using twice per week dosing. Top panel: experimental design. Bottom panel: CTL function in ProHA x
TRAMP mice. 5 animals per group, representative of 2 experiments. C: Comparison of single versus divided dosing of anti-CTLA-4 per week. Top
panel: experimental design. Bottom panel: CTL function in ProHA x TRAMP mice. 5 animals per group, representative of 2 experiments.*P < 0.05.
D: Prostate directed expansion of specific CD8 cells: Top panel: experimental schema. Bottom panels: Absolute numbers of CD8 T cells harvested
from prostate or prostate draining lymph nodes. Left: Absolute number of IFN-γ positive (by intracellular staining) CD8 T cells in those locations. 3
animals per group, representative of 2 experiments. *P < 0.01 (GVAX/α-CTLA-4 mAb vs. GVAX alone).
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ing endogenous CTL function. Although the data ap-
proximate a dose–response relationship, the difference
in CTL function between 6 mg/kg and 9 mg/kg dosing
was not significant. In a dose-dense regimen, we found
that an intraperitoneal dose of 3 mg/kg was signifi-
cantly more effective than 1.5 mg/kg and there was no
significant difference between 3 mg/kg and 6 mg/kg
(Figure 3B). After finding that 6 mg/kg/week produced
a maximal CTL response, we directly compared once
per week and twice per week dosing regimens at this
dose (Figure 3C). A dose of 3 mg/kg (twice/week)
resulted in increased lytic function compared with the
same quantity of antibody administered in a single
weekly bolus at 6 mg/kg. Taken together these datasuggest that relatively low-dose exposure to CTLA-4
blockade might be more efficacious than less frequent
high-dose boluses.
We next returned to an adoptive transfer model to as-
certain whether this regimen would promote expansion
and/or effector function of prostate/prostate cancer spe-
cific CD8 T cells. As shown in Figure 3D, the effects of
the combination regimen were most notable in the tar-
get organ, where a several fold expansion in the absolute
number (left panel) of HA-specific CD8 T cells was
noted. In addition, the majority of these cells secreted
interferon-gamma (IFN-γ) (right panel), consistent with
the acquisition of effector function. These data provide a
mechanistic basis for the increased lytic function me-
diated by the combination regimen.
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GVAX decreases tumor burden and histologic grade in
ProHA x TRAMP mice
To assess whether anti-CTLA-4 could mediate an addi-
tive or synergistic anti-tumor effect, we performed longi-
tudinal treatment studies using ProHA × TRAMP mice.
Age-matched 8–10 week old animals (corresponding to
early disease), were randomly assigned to one of 3 treat-
ment arms: GVAX, anti-CTLA-4, or GVAX + anti-
CTLA-4 mAb. A schematic of the treatment regimen is
depicted in Figure 4A. Ten weeks after initial treatment,
animals were sacrificed and tumor grade and extent
were evaluated in a blinded manner as previously de-
scribed [21,23]. As shown in Figure 4B, scoring of the
microdissected ventral lobes of the prostate glands re-
vealed a significant decrease in tumor score with com-
bination treatment as compared with either treatment
alone. Both GVAX and anti-CTLA-4 monotherapy dem-
onstrated a non-significant trend toward efficacy as
compared with untreated control animals. The wetFigure 4 Longitudinal treatment studies in mice bearing autochronou
score was calculated by multiplying pathological score x extent. All sample
treatment group assignment (See Material and methods). C: Wet weights oweight of the urogenital tract, a gross surrogate for
tumor burden [34], corroborated these data nicely
(Figure 4C). Taken together, these data support a treat-
ment regimen in which relatively low doses of anti-
CTLA-4 are given post-vaccine.
The combination of GVAX and CTLA-4 blockade alters the
phenotype of prostate/prostate-tumor specific CD4 T cells
We next sought to evaluate the impact of anti-CTLA-4
and GVAX combination immunotherapy on tumor
antigen-specific CD4 T cell numbers and function. Simi-
lar to our prior studies of CD8 cells, HA-specific CD4 T
cells (6.5) were adoptively transferred into ProHA ×
TRAMP mice 7 days prior to GVAX treatment. As
shown in Figure 5A, in the absence of specific vaccin-
ation, these cells are difficult to detect after one week in
tumor-bearing mice. This relative lack of persistence was
not affected by anti-CTLA-4 treatment to any appre-
ciable degree; however, GVAX vaccination resulted in a
detectable population of specific CD4 T cells within thes prostate tumors. A: Experimental design. B: Tumor scores. Tumor
s were evaluated by two independent pathologists blinded as to
f the urogenital tract. N = 10 animals per group.
Figure 5 Tumor-specific CD4+ T cell subsets induced by combined therapy. A: Prostate-directed accumulation of HA-specific CD4+ T cells.
Prostate/prostate-cancer specific CD4 T cells from transgenic mice (6.5 strain) were adoptively transferred to tumor-bearing ProHA x TRAMP mice.
After 2 days of in vivo equilibration, mice were treated with GVAX immunotherapy, followed by two doses of anti-CTLA-4 (3 mg/kg) as shown in
the top left panel of Figure 5D. Clonotypic (prostate-specific) CD4 were selected by staining for CD4 and the congenic marker Thy1.1. N = 3
animals per group, representative of 2 experiments. *P < 0.01 (GVAX/anti-CTLA-4 vs GVAX alone), **, P < 0.05 (GVAX/anti-CTLA-4 vs GVAX alone). B:
CD4 T cell subsets expanded by a combination treatment regimen. HA-specific CD4+ T cells were evaluated for secretion of the indicated
cytokines by intracellular staining after a brief ex-vivo stimulation. N = 3 animals per group, representative of 2 experiments. *P < 0.05 (GVAX/anti-
CTLA-4 vs. GVAX alone). C: Combination treatment expands both specific and endogenous regulatory T cells (Treg). Top panel: experimental
design. Bottom Left: HA-specific CD4+FoxP3+ T cells quantified using intracellular staining of lymphocytes harvested from the indicated organs.
Bottom right: Endogenous Treg (experiments performed without adoptive transfer). N = 3 animals per group, representative of 2 experiments.*P
< 0.05 (GVAX/anti-CTLA-4 mAb vs GVAX alone). D: Effects of combination treatment on the Effector / Treg ratio. Prostate / prostate-cancer specific
CD4+ and CD8+ effector T cells (IFN-γ positive) were quantified on day 7 following administration of GVAX + anti-CTLA-4 combination therapy,
and ratios determined by dividing by numbers of Treg as quantified using FoxP3+ intracellular staining. N = 3 animals per group, representative of
2 experiments.
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(Figure 5A). Notably, the combination of anti-CTLA-4
and GVAX vaccination significantly increased the num-
ber of tumor infiltrating CD4 T cells in the prostate
gland, as compared to GVAX therapy alone (Figure 5A).
We next performed intracellular staining (after a brief
ex-vivo stimulation) to determine the phenotype of the
specific CD4 T cells. As shown in Figure 5B, combin-
ation immunotherapy in ProHA × TRAMP mice
resulted in a significant increase in anti-tumor TH1
CD4 cells within the local tumor environment and in
the draining lymph nodes (Figure 5B). In contrast, al-
though there was a trend toward increased numbers of
IL-4 and IL-17 producing tumor antigen-specific CD4
T cells both systemically and locally, these trends were
not statistically significant.CTLA-4 and GVAX combination therapy promotes
expansion of Tregs, but increases antigen-specific CD4+
and CD8+ Teff/Treg ratios
As Tregs have been demonstrated to restrain an anti-
tumor immune response [35,36], we next examined the
impact of combination immunotherapy on the number
of tumor antigen-specific and total Tregs. GVAX + anti-
CTLA-4 mAb combination therapy did not reduce the
number of tumor antigen-specific Tregs (Figure 5C). In
fact, therapy resulted in a significant increase in the ab-
solute numbers of HA-specific CD4+/Foxp3+ T cells in
prostate draining lymph nodes. A similar pattern was
observed for total numbers of CD4+/Foxp3+ T cells, both
systemically and locally. Prior studies have demonstrated
that while combined therapy with GVAX and CTLA-4
blockade may result in increased absolute numbers of
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of an effective anti-tumor response [37]. Hence, we eval-
uated the effects of CTLA-4 blockade and GVAX com-
bination therapy on the tumor antigen-specific Teff and
Treg populations within the tumor and tumor-draining
lymph nodes in our ProHA × TRAMP model. As shown
in Figure 5D, CTLA-4 blockade and GVAX treatment
resulted in an increase in the ratio of tumor antigen-
specific CD4 and CD8 Teffs to Tregs. Interestingly, this
effect was quite dramatic in tumor tissue, for both CD4
and CD8 T cells. Taken together these data support a
model wherein combination treatment increases the
number of both CD4 and CD8 effector cells, in addition
to a relative increase in the Teff: Treg ratio for both T
cell subtypes.
Transient depletion of tregs with low-dose
cyclophosphamide augments the anti-tumor effects of
combination immunotherapy
Although multiple studies have shown that tumor im-
munotherapy is most likely to be successful in a setting
of lower disease burden [38], the majority of clinical
studies have been conducted in men with castrate-
resistant, metastatic disease [8]. We thus sought to de-
termine the relative efficacy of combination GVAX/anti-
CTLA-4 therapy in models of metastatic disease, both in
the presence and absence of primary tumor. For these
studies, we derived a unique cell line (SP1) from the
prostate gland of a late-stage ProHA × TRAMP mouse.
This line, SP1, is class I positive, and expresses low levels
of HA. We first modeled pulmonary metastases (by I.V.
injection of tumor cells) in both wild type and tumor
bearing mice. Three days after tumor cell injection, mice
were treated with either combination therapy (GVAX +
anti-CTLA-4), or each treatment alone (Figure 6A). As
show in Figure 6B, combination treatment was not able
to significantly delay mortality on the tolerant ProHA ×
TRAMP background. Similar results were noted in non-
tolerant B10.D2 (wildtype mice), but here a small pro-
portion of mice were able to survive long-term. These
data underscore the challenges involved in treating
metastatic disease, particularly in the setting of pre-
existing tolerance. Similar results were obtained in a
model of liver metastases [33] as a significant survival
benefit was observed only in non-transgenic mice
(Figure 6C).
In a final series of studies, we explored the possibility
that the expansion of Tregs mediated by GVAX and
anti-CTLA-4 combination treatment limits the immune
response. We thus repeated the pulmonary metastasis
studies shown in Figure 6B, with the addition of low
dose cyclophosphamide (50 mg/kg) to our treatment
regimen [23]. As shown in Figure 6D, the addition of
cyclophosphamide significantly improved overall survivalin animals with concurrent primary and metastatic dis-
ease as well as non-transgenic animals with metastatic tu-
mors, reliably resulting in a small population of long-term
disease-free mice in endogenously tolerant (ProHA ×
TRAMP) as well as wild-type mice.
Discussion
Ipilimumab, a monoclonal antibody blocking the im-
mune checkpoint CTLA-4, has recently been evaluated
in two randomized, Phase III, placebo-controlled trials
in men with metastatic, castrate-resistant prostate can-
cer. In one study, the agent was administered as mono-
therapy to chemotherapy-naïve men (NCT01057810). In
the second trial (NCT00861614), ipilimumab was ad-
ministered in combination with low-dose radiotherapy
to one or more bone lesions in patients who had
progressed after docetaxel chemotherapy. Mature data
from these trials are not yet available. Combination regi-
mens involving ipilimumab and immunotherapy have
also been evaluated in Phase I clinical trials. Recently,
Madan et al. showed that ipilimumab could be safely
combined with the PSA-targeted vaccine PSA-Tricom,
without significantly exacerbating the agent’s immune-
related adverse event profile [39]. Interestingly, over 50%
of the patients in this study who were chemotherapy-
naïve experienced a PSA decline from baseline levels.
Perhaps most relevant to our current data, the Gerritsen
group performed a Phase I study to determine whether
ipilimumab could safely be combined with GVAX pros-
tate [40]. Those results were also encouraging, demon-
strating the tolerability of the combined regimen and
providing early evidence for efficacy. Taken together,
these clinical trials highlight a need for preclinical stud-
ies that use relevant (immunologically tolerant) animal
models to optimize dosing and sequencing.
We examined the anti-tumor effects of combination
therapy with GVAX and anti-CTLA-4 in an autochthon-
ous prostate cancer model expressing HA in a prostate-
restricted manner. Although previous preclinical studies
have demonstrated that CTLA-4 blockade augments the
anti-tumor effects of GVAX [18], to our knowledge this
is the first study to report extensively on the importance
of timing and dosage in this treatment regimen. Our
data show that GVAX + anti-CTLA-4 combination ther-
apy mitigates peripheral tolerance and promotes the
activation and proliferation of tumor antigen-specific
CD8 T cells. While GVAX immunotherapy alone
induced proliferation of HA-specific CD8 T cells in non-
transgenic animals, this effect was significantly blunted
in ProHA × TRAMP mice, confirming previous findings
that T cells become refractory to tumor antigens in the
setting of endogenously arising prostate tumors [19]. In
addition, our results indicate that the percentage of T
cells comprising the CD8 HA-specific T cell population
Figure 6 Anti-tumor effects of combined therapy in models of pulmonary and hepatic metastases. A: Treatment regimen. B: Treatment
effect in a pulmonary metastasis model. Cohorts of 20–22 week old ProHA x TRAMP mice (left panel) or non-transgenic (right panel) received I.V.
injections of tumor cells (SP1) and were then treated with either combination or single-agent immunotherapy. N = 7 animals per group,
representative of 2 independent experiments. *P < 0.05 (GVAX/anti-CTLA-4 vs. No Treatment.). C: Treatment effect in a hepatic metastasis model.
Cohorts of 20–22 week old ProHA x TRAMP mice (left panel) or non-transgenic (right panel) received intra-splenic injection of tumor cells (SP1),
followed by resection of the injected hemispleen to model isolated heptatic metastases. Animals were then treated with either combination
immunotherapy or left untreated. N = 7 animals per group, representative of 2 independent experiments. *P < 0.05 (GVAX/anti-CTLA-4 vs No
Treatment.). D: Addition of low-dose cyclophosphamide to combination immunotherapy. 20–22 week ProHA x TRAMP mice or non-transgenic
mice were intravenously injected with the prostate cancer cell line (SP1). Cyclophosphamide (50 mg/kg) was administered 1 day before each
GVAX injection. The treatment regimen was otherwise identical to that shown in 6A. N = 7 animals per group. Representative of 2 experiments.
*P < 0.05 (Cy/GVAX/anti-CTLA-4 vs GVAX/anti-CTLA-4).
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animals, but reached a plateau at day 4 in tumor-bearing
mice. Expression of CTLA-4 on CD8 HA-specific T cells
in prostate and prostate draining lymph nodes signifi-
cantly increased between days 4 and 7 in tumor bearing
mice. Consistent with previous studies [20], these data
indicate that ProHA × TRAMP mice harbor tumors
which induce tolerance that is mediated, at least to some
degree, by increased CTLA-4 expression on CD8 T cells,
although effects on CD4 T cells, as well as priming
stages of the immune response, are likely also involved.
Administration of GVAX followed by anti-CTLA-4
resulted in a significant increase in the percentage of HA-
specific CD8+ T cells at days 7 and 10. The efficacy of this
treatment regimen, however, was highly dependent uponthe dose and relative timing of GVAX and anti-CTLA-4
administration. Interestingly, while administration of anti-
CTLA-4 at days 1 and 4 post-GVAX resulted in a sig-
nificant increase in target cell lysis, this effect was not
observed when anti-CTLA-4 was administered on day −1.
There are a number of potential explanations for this ef-
fect. Perhaps the simplest explanation is that the anti-
CTLA-4 mAb migrates to multiple sites of CTLA-4
expression (i.e. the gut), and that expression of CTLA-
4 on tumor-specific T cells is not particularly robust
until after antigen-specific vaccination. This explan-
ation is supported by our data, which show relatively
delayed kinetics of CTLA-4 expression after vaccin-
ation (Figure 1). A second possibility is that the admin-
istration of anti-CTLA-4 results in a compensatory
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vents generation of an effective anti-tumor response when
GVAX vaccine is administered later. While additional
studies might be helpful in elucidating the underlying
mechanism, it is clear from our data that administration
of GVAX prior to anti-CTLA-4 was superior in stimulat-
ing anti-tumor CD8 T cell activity as compared with up-
front administration of anti-CTLA-4 or either therapy
alone. This finding has clear clinical significance. In
addition, our data demonstrate that there was no differ-
ence in administration of anti-CTLA-4 mAb on day +1 vs.
day +4 in once-per-week or twice-per-week dosing regi-
mens. Anti-CTLA-4 mAb dose-escalation studies demon-
strated the greatest effects between 3 mg/kg and 6 mg/kg
in the once per week dosing regimen and, correspond-
ingly, 1.5 mg/kg and 3 mg/kg in the twice per week dosing
regimen. In a direct comparison of dosing regimens at
6 mg/kg/week, we found twice per week dosing to be su-
perior to once-per-week dosing. Based on these data, we
concluded that the treatment regimen that produced opti-
mal CD8 T cell anti-tumor activity was day 0 GVAX
followed by twice per week anti-CTLA-4 mAb at the dose
of 3 mg/kg.
After determining the optimal treatment regimen for
GVAX + anti-CTLA-4 in our ProHA × TRAMP model,
we sought to more thoroughly explore the underlying
immunologic mechanisms. Our data clearly demonstrate
an increase in the absolute number of HA-specific CD8
T cells as well as an increase in the number of IFN-γ
producing cells in the prostate gland and prostate
draining lymph nodes. Interestingly, there was also a
trend toward decreased numbers of HA-specific CD8 T
cells in the prostate draining lymph nodes with combin-
ation therapy as compared with GVAX therapy alone.
Given that this effect was not observed in prostate tis-
sue, it is reasonable to speculate that treatment with
anti-CTLA-4 mAb may increase trafficking of tumor
antigen-specific T cells into tumor tissue [41].
Although combination therapy with GVAX and CTLA-4
blockade increases tumor antigen-specific CD8 T cell pro-
liferation and activation, this has not been consistently
shown to correspond with tumor eradication or improved
survival [42], so we used tumor score and weight of the
genital tract as direct measures of effectiveness in a
relevant preclinical model. We found that the tumor
score was significantly lower for animals receiving
combination therapy as compared with control animals or
animals receiving either therapy alone. Of note, 3 of the
10 mice receiving combination therapy had no histologic
evidence of disease, while tumors were identified in every
mouse in the other treatment arms. The weight of the
urogenital tract corroborated these findings as the uro-
genital tracts of animals receiving combination therapy
weighted significantly less than animals in the othertreatment arms. These data support the potential clinical
utility of the combination regimen.
In addition to expanding the CD8 T cell compartment,
CTLA-4 blockade has been shown to affect various CD4
T cell populations, including Tregs [43] and Th17 cells
[44]. Therefore, we evaluated the response of these cell
populations to our treatment regimen. Combination
therapy resulted in skewed local and systemic expansion
of the HA-specific CD4 T cell compartment toward an
anti-tumor, IFN- γ+ phenotype. Our data further suggest
that this expansion may include other CD4 T cell sub-
types as there was a non-statistically significant trend to-
ward increased numbers of HA-specific CD4+/IL-4+,
CD4+/IL-17+, and CD4+/FoxP3+ T cells. Expansion of
the Th17 compartment is consistent with previous stud-
ies [44] and, although these cells have been traditionally
considered pro-tumorigenic, there is some evidence to
suggest that they may play a role in anti-tumor immune
responses as well [45]. The finding that the numbers of
HA-specific and total Tregs are increased is also consist-
ent with previous studies [14]. Our data suggest that,
while combination treatment induces Treg expansion,
treatment also increases tumor antigen-specific CD4
Teff/Treg and CD8 Teff/Treg ratios.
Since depletion of Tregs may be associated with im-
proved survival in patients with metastatic castration-
resistant prostate cancer responding to vaccines [46], we
sought to determine whether the addition of low-dose
cyclophosphamide further augments the GVAX + anti-
CTLA-4 treatment effect in models of pulmonary and
hepatic metastasis. Analogous to our previous finding
that GVAX alone failed to induce HA-specific CD8 T
cell proliferation in ProHA × TRAMP mice, combi-
nation therapy increased survival in non-transgenic
animals with pulmonary or hepatic metastases, but failed
to do so in ProHA × TRAMP animals harboring auto-
chronous prostate tumors. The addition of cyclophos-
phamide (50 mg/kg) to this treatment regimen, however,
resulted in improved survival in the non-transgenic ani-
mals and rescued the survival advantage in ProHA ×
TRAMP animals. Mechanistically, these results generally
support the notion that the Teff/Treg ratio correlates
with anti-tumor immunity in immunotherapy regimens;
however, these data should be interpreted with some
caution, since low-dose cyclophosphamide has favorable
effects on several other immune cell populations. In par-
ticular, this regimen promotes DC secretion of type I
IFN, affects DC turnover, and modifies DC phenotype
[47]. Thus, there are a number of plausible, competing
explanations for the observed effect.
Conclusion
These experiments corroborate recent clinical data,
which suggest that the combination of CTLA-4 blockade
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significant anti-tumor effects in men with prostate can-
cer. Our data indicate that the therapeutic window of
such an approach may be maximized through meticu-
lous study of various doses and dosing regimens. Fur-
thermore, Tregs appear to be a limiting factor in this
treatment regimen such that depletion of this cell popu-
lation enhances anti-tumor immunity. Based on these
data, clinical studies may find that the addition of cyclo-
phosphamide to this treatment regimen allows for re-
duction in the dose of anti-CTLA-4, potentially limiting
autoimmune toxicity. Since recently reported trials
[39,40], show that ipilimumab can safely be administered
in combination with immunotherapy to men with pros-
tate cancer, it seems logical to consider the initiation of
future trials in which anti-CTLA-4 is combined with
GVAX immunotherapy and low-dose cyclophosphamide,
most likely in the earlier stages of metastatic disease.
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